Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2017; 17(4):298-301
DOI: 10.5428/pcar20170415
Empirical research on the price level of drugs for non-communicable diseases in basic drug list of Shanghai Qingpu District
1. SHEN Yi1(1.Department of Pharmacy,Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University,Shanghai 201700,China syzp987@163.com)
2. WANG YongFeng2( 2.Department of Medical Administration,Health and Family Planning Commission,Shanghai Qingpu District,Shanghai 201700,China )
3. XIE Ning1(1.Department of Pharmacy,Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University,Shanghai 201700,China )
4. WAN Qian1(1.Department of Pharmacy,Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University,Shanghai 201700,China )
5. LI Hui1(1.Department of Pharmacy,Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University,Shanghai 201700,China )
6. TANG KouMing1(1.Department of Pharmacy,Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University,Shanghai 201700,China menshishan@126.com)
ABSTRACT  Objective: To evaluate the price level of medicines for non-communicable diseases in basic medicine list of Shanghai Qingpu district,so as to provide solid evidences and suggestions for the promotion of price rationality of basic medicines in the community.Methods: The median price ratio (MPR) of 47 nomenclature medicine was calculated by purchasing power parity coefficient with the standard survey method recommended by WHO/HAI.Results: The MPR of 47 nomenclature medicines in the investigation was 7.48,the MPR of original brand (OB) and the lowest-price me-too medicines (LPMMs) were 16.26 and 3.33,respectively.The price and the difference of OB were greater than those of the LPMMs,and median rate of their MPR was 2.86.The MPR of OB salbutamol was less than that of LPMM salbutamol.Conclusion: The price level of the community NCDs basic medicines is relatively high.A series of policy intervention is required to achieve a reasonable price level of the OB and most of LPMMs.
Welcome to PCAR! You are the number 48 reader of this article!
Please cite this article as:
SHEN Yi1,WANG YongFeng2,XIE Ning1,WAN Qian1,LI Hui1,TANG KouMing1,. Empirical research on the price level of drugs for non-communicable diseases in basic drug list of Shanghai Qingpu District[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(4): 298-301.
References:
1. WHO.Global Status Report on noncommunicable diseases 2014[R].Switzerland: 2014.
2. Vialle-Valentin C E,Serumaga B,Wagner A K,et al.Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries[J].Health Policy Plan,2014:1-9.
3. WHO.Noncommunicable diseases country profiles 2014[R].Switzerland: 2014.
4. MSH.International Drug Price Indicator Guide (2014 ed)[EB/OL].[2016-08-10]. http://erc.msh.org/dmpguide/pdf/DrugPriceGuide_2014.pdf.
5. WHO, HAI.Measuring medicine prices,availability,affordability and price components (2nd ed)[EB/OL].[2016-08-10].http://www.who.int/medicines/areas/access/medicines_prices08/en/.
6. GUAN XiaoDong,SHI LuWen.Study on the evaluation method for the accessibility of essential medicine in China based on WHO/HAI standardized approach[J].China Pharmacy,2013,24(24):2212-2215.In Chinese with English abstract.
7. National Bureau of Statistics of China.The price index[EB/OL].[2016-08-10].http://data.stats.gov.cn/easyquery.htm?cn=C01.In Chinese.
8. OECD. PPPs and exchange rates[EB/OL].[2016-08-10].http://stats.oecd.org/index.aspx?datasetcode=SNA_TABLE4.
9. Mendis S,Fukino K,Cameron A,et al.The availability and affordability of selected essential medicines for chronic diseases in six low and middle income countries[J].Bull World Health Org,2007,85 (4):279-288.
10. van Mourik MSM,Cameron A,Ewen M,et al.Availability,price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data[J].BMC Cardiovasc Disord,2010,10:25.
11. Babar Z U D,Lessing C,Mace C,et al.The availability,pricing and affordability of three essential asthma medicines in 52 low and middle income countries[J].PharmacoEconomics,2013,31:1063-1082.
12. LUO Zhu,LIU ChunTao,WU SongZe,et al.Pharmacodynamic evaluation of salbutamol sulfate metered-dose inhalers with HFA-134A propellant[J].Chin J New Drugs,2014,23(6):682-685.In Chinese with English abstract.
13. WANG SiOu,LIU Yang,GUAN XiaoDong.Empirical study on the essential drugs’ price in parts of China[J].Chin Health Serv Manage,2011,(4):266-267,309.In Chinese with English abstract.
14. YE Lu.A survey of medicine prices,availability and affordability in Shanghai,China using the WHO/HAI methodology[R].Shanghai: 2006.
15. YU Fang.Medicine prices,availability and affordability in Shanxi Province,Western China[R].Xi’an:2012.
16. ZHANG Fang,ZHAO Chen.Analysis of the individual pricing system of the originator brand[J].Chin J Drug Eval,2012,29(2):163-166.In Chinese.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口